Navigation Links
Avidas(TM) Pharmaceuticals Introduces Scalacort(TM) DK Which Offers Three Scalp Solutions in One Patient Convenience Kit
Date:3/24/2009

DOYLESTOWN, Pa., March 24 /PRNewswire/ -- Avidas(TM) Pharmaceuticals, a privately held, specialty pharmaceutical company which focuses on dermatology and women's health, today announced the launch of Scalacort(TM) DK (defence kit), that offers three scalp solutions in one patient convenience kit.

Scalacort DK includes Scalacort (hydrocortisone lotion USP) 2%, a fast-drying, non-greasy, corticosteroid in a clear fragrance-free base. Scalacort relieves itching and inflammation of the scalp in areas where greasy ointments and creams may not be cosmetically appealing. For added patient convenience Scalacort DK also includes the following complimentary products: defence(TM) medicated shampoo, a professional-strength medicated shampoo formulated with 2% salicylic acid and 2% micronized colloidal sulfur to control the flaking and scaling of seborrheic dermatitis and scalp psoriasis; and defence(TM) gentle cleansing shampoo, a color- and fragrance-free, non-irritating shampoo designed to be used daily on all hair types. Scalacort DK is available by prescription only.

Seborrheic dermatitis (also known as seborrheic eczema) is one of the most common cutaneous disorders affecting approximately eight million Americans. According to the American Academy of Dermatology (AAD), seborrheic dermatitis cannot be cured but in most cases will respond quickly to proper treatment. The goals of treatment are to loosen and remove scales and crusts, prevent skin infections, as well as reduce the inflammation and itch. Scalp psoriasis, another common skin disorder affecting approximately four million Americans, shares the same treatment goals of removing scales and crusts along with reducing inflammation and itch.

"Patient convenience is important to treatment outcomes," said Millburn, New Jersey dermatologist Dr. Gail H. Mautner. "With Scalacort DK physicians can, with one prescription, provide their patients with three scalp products in a single convenience kit."

A valuable patient prescription co-pay coupon is available at http://www.ScalacortDK.com

About Scalacort:

Scalacort is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Important Safety Information:

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary- adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

Please see Scalacort full prescribing information at http://www.ScalacortDK.com

About Seborrheic Dermatitis:

Seborrheic dermatitis is a chronic inflammatory disorder affecting areas of the head and trunk where sebaceous glands are most prominent. Lipophilic yeasts of the Malassezia genus, as well as genetic, environmental and general health factors, contribute to this disorder. Scalp seborrhea varies from mild dandruff to dense, diffuse, adherent scale.

Facial and trunk seborrhea is characterized by powdery or greasy scale in skin folds and along hair margins.

About Scalp Psoriasis:

Psoriasis is a chronic, non-contagious autoimmune disease which affects the skin and joints. It commonly causes red scaly patches to appear on the skin. The scaly patches caused by psoriasis, called psoriatic plaques, are areas of inflammation and excessive skin production. Skin rapidly accumulates at these sites and takes on a silvery-white appearance. Approximately half of the people who have psoriasis have scalp psoriasis.

About Avidas:

Avidas Pharmaceuticals is a privately held company focused on the therapeutic areas of dermatology and women's health. The company acquires, develops, and maximizes the potential of acquired products through focused selling and precision marketing. The Company is headquartered in Doylestown, PA. http://www.avidaspharma.com

Contact: Avidas Pharmaceuticals, LLC, Greg Gironda, 267-895-1755, greggironda@avidaspharma.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Avidas Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... assessments and consulting services, has published a new eBook titled “ 5 Questions ... Bridge, MSc, Associate Research Analyst on the Genetic Test Evaluation (GTE) team, the ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider of ... clinical trials market. Similar to its approach in demonstrating positive outcomes in the healthcare ... by proving the value of eVisits to support virtual studies. , In ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... Fort Lauderdale, FL (PRWEB) , ... June 20, 2017 , ... ... Flex, a new scrub collection featuring seven new products designed to create tailored looks ... a mixture of polyester and cotton easy care stretch twill. , With trendy looks ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, a healthcare ... officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. , ... in healthcare will provide invaluable direction for the company,” says Andrew Hoffman, President ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. (NYSE: ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, in ... Greisch , Hill-Rom,s president and chief executive officer, is scheduled ... live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm . ... of the live event through September 13, 2017. ...
(Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
Breaking Medicine Technology: